Secondary analysis of a phase 3 RCT in PBC with inadequate response or intolerance to ursodeoxycholic acid: seladelpar 10 mg vs placebo over 12 months improved itch severity (NRS ≥4 subgroup) and itch-related sleep disturbance.
Secondary analysis
Levy et al. Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial